Orthopedics specialist Zimmer is trying to expand the market for its artificial joints by appealing to younger patients. Its strategies to do so are on display at the annual meeting of the American Academy of Orthopaedic Surgeons meeting in Las Vegas.
Startup TVA Medical boasted about a recent study which found that its clinical-stage device to give chronic kidney disease patients vascular access to a hemodialysis machine was successful 97% of the time.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
The tick-borne parasite that causes East Coast fever kills 1 million cows per year. Now University of Edinburgh scientists are proposing that a vaccine be made from a related--but far less deadly--parasite.
At the American Academy of Orthopedic Surgeons meeting in Las Vegas, Zimmer touted its new training program enabling patients with its new Persona Knee System to be treated in an outpatient setting.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.
With Sun Pharmaceutical's $4 billion buyout of Ranbaxy Laboratories all but wrapped up, the combined company has plenty on its plate: get plants banned by the FDA in order, get more products approved and to the market and find $250 million in savings with minimal layoffs.
Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.
As Big Pharma casts an eye toward med tech to diversify its offerings and capitalize on a growing market, Novartis is jumping on the bandwagon with new digital and patient monitoring devices.